Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2021 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of...
May 14, 2021 18:25 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are: Treatment naïveSwitching from C5 inhibitor Soliris® (eculizumab) Switching from C5 inhibitor Ultomiris®...
May 12, 2021 10:06 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal...
May 07, 2021 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
April 28, 2021 16:01 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results

Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action date of May 14,...
April 21, 2021 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021

WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
April 16, 2021 12:44 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration Presentations support the potential of intravitreal pegcetacoplan, an investigational...
April 13, 2021 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy

Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007)Top-line data from Phase 3 DERBY...
March 17, 2021 17:48 ET | Source: Apellis Pharmaceuticals, Inc.; Sobi

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels...
March 10, 2021 09:15 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass.,...